Recce Pharmaceuticals logo

RCE - Recce Pharmaceuticals Share Price

A$1.18 0.1  7.8%

Last Trade - 7:10am

Small Cap
Market Cap £105.5m
Enterprise Value £92.5m
Revenue £412k
Position in Universe 655th / 1896
Unlock RCE Revenue
Relative Strength (%)
1m +5.24%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.11 0.18 0.19 1.30 0.69 1.15 +58.7%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ReccePharmaceuticals Ltd revenues decreased 37% to A$677K. Netloss increased from A$1.3M to A$10.2M. Revenues reflectAustralia segment decrease of 69% to A$228K, USA segmentdecrease of 34% to A$222K. Higher net loss reflectsStock-based Compensation in SGA increase from A$33K toA$4.7M (expense), Selling/General/Admin. Expense increasefrom A$726K to A$3.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RCE
Graphical History


RCE Revenue Unlock RCE Revenue

Net Income

RCE Net Income Unlock RCE Revenue

Normalised EPS

RCE Normalised EPS Unlock RCE Revenue

PE Ratio Range

RCE PE Ratio Range Unlock RCE Revenue

Dividend Yield Range

RCE Dividend Yield Range Unlock RCE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RCE EPS Forecasts Unlock RCE Revenue
Profile Summary

Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated April 11, 2007
Public Since January 15, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX All Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 173,711,175
Free Float (0.0%)
Eligible for
RCE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RCE
Upcoming Events for RCE
Frequently Asked Questions for Recce Pharmaceuticals
What is the Recce Pharmaceuticals share price?

As of 7:10am, shares in Recce Pharmaceuticals are trading at A$1.18, giving the company a market capitalisation of £105.5m. This share price information is delayed by 15 minutes.

How has the Recce Pharmaceuticals share price performed this year?

Shares in Recce Pharmaceuticals are currently trading at A$1.18 and the price has moved by 0.253k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Recce Pharmaceuticals price has moved by 0.171k% over the past year.

What are the analyst and broker recommendations for Recce Pharmaceuticals?

There are no analysts currently covering Recce Pharmaceuticals.

When will Recce Pharmaceuticals next release its financial results?

Recce Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Recce Pharmaceuticals dividend yield?

Recce Pharmaceuticals does not currently pay a dividend.

Does Recce Pharmaceuticals pay a dividend?

Recce Pharmaceuticals does not currently pay a dividend.

When does Recce Pharmaceuticals next pay dividends?

Recce Pharmaceuticals does not currently pay a dividend.

How do I buy Recce Pharmaceuticals shares?

To buy shares in Recce Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Recce Pharmaceuticals?

Shares in Recce Pharmaceuticals are currently trading at A$1.18, giving the company a market capitalisation of £105.5m.

Where are Recce Pharmaceuticals shares listed? Where are Recce Pharmaceuticals shares listed?

Here are the trading details for Recce Pharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: RCE
What kind of share is Recce Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Recce Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Recce Pharmaceuticals share price forecast 2021?

We were not able to load any forecast data for Recce Pharmaceuticals.

How can I tell whether the Recce Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Recce Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -8.37%. At the current price of A$1.18, shares in Recce Pharmaceuticals are trading at -2.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Recce Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Recce Pharmaceuticals.

Who are the key directors of Recce Pharmaceuticals?

Recce Pharmaceuticals's management team is headed by:

Michele Dilizia - CSO
James Graham - CEO
Alistair McKeough - SEC
John Prendergast - CHM
Justin Ward - DRC
Alan Dunton - NID
Who are the major shareholders of Recce Pharmaceuticals?

Here are the top five shareholders of Recce Pharmaceuticals based on the size of their shareholding:

Melrose (Graham John Hamilton Ph.D.) Individual Investor
Percentage owned: 20.98% (36.5m shares)
Gustafson (Ross) Individual Investor
Percentage owned: 4.02% (6.99m shares)
Graham (James Hamilton Bray) Individual Investor
Percentage owned: 3.44% (5.98m shares)
Fidelity Funds - Pacific Fund Mutual Fund
Percentage owned: 3.13% (5.44m shares)
Fidelity International Investment Advisor
Percentage owned: 3.13% (5.44m shares)
Similar to RCE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.